PhRMA CEO Steve Ubl discusses, PBM reform, the "pill penalty" with the administration and advocating for pharmaceutical ...

Swiss generic drug manufacturer Sandoz has agreed to pay $275 million to resolve claims by U.S. consumers and others who ...

The DOJ backs Medicare price negotiations amidst a Novartis lawsuit, while President Trump vows to lower U.S. drug costs.

A new study from the USC Schaeffer Center shows that out-of-pocket costs for brand-name medications have increased sharply ...

Expected out-of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...

Topline: Taxpayers spent $74.5 million to help develop the prostate cancer-fighting drug Xtandi, but its sky-high sticker ...

The U.S. Department of Justice has filed an appeals court brief supporting the right of Medicare officials to negotiate ...

Providers are sympathetic to Medicare enrollees’ concerns but don’t agree on their role in helping patients find less costly ...

Debate over whether or not the Affordable Care Act, commonly known as Obamacare, worked and how President Trump's executive ...

While Trump's tariffs could have a broad impact on healthcare prices, it is likely they will not have the devastating result ...

Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper ...

CHICAGO—On the heels of his 2025 State of the State budget address, Governor Pritzker focused on one of his top legislative ...